[ad_1]
VIKEN, Sweden – November 2, 2018 – (Newswire.com)
TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological diseases, announced today that the first patient with Amyotrophic Lateral Sclerosis (ALS) has been treated with the company's investigational drug ILB, in the on-going clinical trial at Sahlgrenska. University Hospital in Gothenburg, Sweden.
Anders Svenson M.D., Chief Medical Officer of TIKOMED, commented"We are very pleased that our clinical trial, with our investigational drug ILB for the treatment of ALS, is well under way and that the trial has been successfully completed with ILB. We believe this clinical trial, conducted at Sahlgrenska University Hospital, will demonstrate the safety and tolerability of ILB in the treatment of ALS. "
With Dr. Lennart Persson as Principal Investigator, the clinical trial is conducted with Sahlgrenska University Hospital in Gothenburg. 15 patients with ALS will receive ILB for a four-week treatment period followed by a follow-up period.
Anders Kristensson, Chief Executive Officer of TIKOMED, commented"With ILB we present a potential new cause of neurodegeneration, as seen in a chronic ALS. We are committed to bringing forward ALS clinical trials and hopefully one step closer to ALS sufferers battling this fatal disease. "
TIKOMED will also be running at phase II ALS study in collaboration with Birmingham University in Birmingham, UK. In this trial, 15 patients with ALS will receive ILB for a ten-week treatment period.
Related Links
website
Press Release Service
by
Newswire.com
Original Source:
First Patient Treated With ILB in TIKOMED's Clinical Trial for ALS
[ad_2]
Source link
